Impact of intermediate to high doses of methylprednisolone on mortality rate in patients with COVID-19 pneumonia-induced severe systemic inflammation.

INTRODUCTION: In addition to respiratory support needs, patients' characteristics to guide indication or timing of corticosteroid treatment in COVID-19 patients are not completely established. This study aimed to evaluate the impact of methylprednisolone on mortality rate in patients with COVID-19 pneumonia-induced severe systemic inflammation (PI-SSI). METHODS: Between 9 March and 5 May 2020 (final follow-up on 2 July 2020), a retrospective cohort study was conducted in hospitalised patients with COVID-19 PI-SSI (≥2 inflammatory biomarkers [IBs]: temperature ≥38℃, lymphocyte ≤800 cell/µL, C-reactive protein ≥100 mg/L, lactate dehydrogenase ≥300 units/L, ferritin ≥1000 mcg/L, D-dimer ≥500 ng/mL). Patients received 0.5-1.0 mg/kg of methylprednisolone for 5-10 days or standard of care. The primary outcome was 28-day all-cause mortality. Secondary outcomes included ≥2 points improvement on a 7-item WHO-scale (Day 14), transfer to intensive care unit (ICU) (Day 28) and adverse effects. Kaplan-Meier method and Cox proportional hazard regression were implemented to analyse the time to event outcomes. RESULTS: A total of 142 patients (corticosteroid group n = 72, control group n = 70) were included. A significant reduction in 28-day all-cause mortality was shown with methylprednisolone in patients with respiratory support (HR: 0.15; 95% CI 0.03-0.71), with ≥3 (HR: 0.17; 95% CI 0.05-0.61) or ≥4 altered IB (HR: 0.15; 95% CI 0.04-0.54) and in patients with both respiratory support and ≥3 (HR: 0.11; 95% CI 0.02-0.53] or ≥4 altered IB (HR: 0.14; 95% CI 0.04-0.51). No significant differences were found in secondary outcomes. CONCLUSION: Intermediate to high doses of methylprednisolone, initiated between 5 and 12 days after symptom onset, was associated with a significant reduction in 28-day all-cause mortality in patients with COVID-19 pneumonia and ≥3 o ≥ 4 altered IB, independently of the need of respiratory support.

Suction catheter guided insertion of the ProSeal laryngeal mask airway is superior to the digital technique.

PURPOSE: We tested the hypothesis that digital insertion of the ProSeal laryngeal mask airway (ProSeal LMA) is more successful when using a suction catheter (SC) as a guide. METHODS: Two hundred and forty-three patients (ASA physical status I-III; aged 18-84 yr) were randomly allocated for the digital or SC-guided technique. The digital technique was performed according to the manufacturer's instructions. The SC technique involved priming the drain tube with the SC so that it protruded by 15 cm, blindly inserting the SC into the pharynx to a depth of 15 cm, followed by the digital technique. Failed insertion was defined by any of the following criteria: 1) failed passage into the pharynx; 2) malposition; and 3) ineffective ventilation. Any airway trauma, and visible or occult blood was noted. Sore throat, dysphonia and dysphagia were assessed 16 to 24 hr postoperatively. RESULTS: Fewer insertion attempts were required with the SC-guided technique (P = 0.02), but first attempt and overall success were similar. The time taken to provide an effective airway was shorter for the SC-guided technique (36 +/- 24 sec vs 44 +/- 28 sec, P = 0.02). A lateral approach was required less frequently with the SC-guided technique (0% vs 4%, P = 0.0004). There were no adverse events. Mouth trauma was more frequent with the digital technique (P = 0.04), but overall trauma was similar. There were no differences in the frequency of visible or occult blood. There were no differences in postoperative airway morbidity. CONCLUSIONS: The SC-guided technique is more frequently successful than the digital technique and is associated with less mouth trauma during insertion of the ProSeal LMA. We suggest that the SC technique may be a useful alternative when the digital technique fails.